Teva Pharmaceutical gets FDA approval for AUSTEDO XR for TD and HD
Teva Pharmaceutical Industries said that its US affiliate Teva Pharmaceuticals has secured approval for AUSTEDO XR (deutetrabenazine) extended-release tablets from the US Food and Drug Administration (FDA) for tardive dyskinesia (TD) and chorea associated with Huntington’s disease (HD). AUSTEDO XR is a new daily once formulation. Expected to be launched in the US later this […]